Journal ArticleDOI
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.
TLDR
In the present studies the neuroprotective activity of rasagiline is blocked by ERK inhibitor, PD98059 (20 microM), suggesting the involvement of PKC-MAP kinase pathway in the neuroprotection.About:
This article is published in Neuroscience Letters.The article was published on 2004-01-30. It has received 157 citations till now. The article focuses on the topics: Rasagiline & Selegiline.read more
Citations
More filters
Journal ArticleDOI
The Role of Oxidative Stress in Parkinson’s Disease
TL;DR: Animal models of PD have yielded some insights into the molecular pathways of neuronal degeneration and highlighted previously unknown mechanisms by which oxidative stress contributes to PD, but therapeutic attempts to target the general state of oxidative stress in clinical trials have failed to demonstrate an impact on disease progression.
Journal ArticleDOI
Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases
Andrea Cavalli,Maria Laura Bolognesi,Anna Minarini,Michela Rosini,Vincenzo Tumiatti,Maurizio Recanatini,Carlo Melchiorre +6 more
TL;DR: The aims of the present article are to discuss the role of ligand modification in the discovery of clinically efficacious drugs and the role that ligands endowed with outstanding in vitro selectivity have in this area.
Journal ArticleDOI
Advances in the treatment of Parkinson's disease.
TL;DR: The limitations of currently available therapies and the most recent research regarding neuroprotective agents, antioxidants, stem cell research, vaccines and various surgical techniques available and being developed for the management of PD are summarized.
Journal ArticleDOI
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases.
TL;DR: Both experimental and epidemiological evidence demonstrate that flavonoid polyphenols, particularly from green tea and blueberries, improve age‐related cognitive decline and are neuroprotective in models of PD, AD and cerebral ischemia/reperfusion injuries.
Journal ArticleDOI
Novel pharmacological targets for the treatment of Parkinson's disease
Anthony H.V. Schapira,Erwan Bezard,Jonathan M. Brotchie,Frédéric Calon,Graham L. Collingridge,Borris Ferger,Bastian Hengerer,Etienne C. Hirsch,Etienne C. Hirsch,Peter Jenner,Nicolas Le Novère,Jose A. Obeso,Michael A. Schwarzschild,Umberto Spampinato,Giora Davidai +14 more
TL;DR: This review describes the important recent advances that underlie the development of novel dopaminergic and non-dopaminergic drugs for Parkinson's disease, and also for the motor complications that arise from the use of existing therapies.
References
More filters
Journal ArticleDOI
A controlled trial of rasagiline in early Parkinson disease: The tempo study
Andrew Siderowf,Matthew B. Stern,Ira Shoulson,Karl Kieburtz,David Oakes,Denni Day,Aileen Shinaman,Sandra Plumb,Stanley Fahn,Karen Blindauer,Mark F. Lew,Howard I. Hurtig,Mary Lloyd,Robert A. Hauser,Lisa Gauger,Lawrence I. Golbe,Joanne Wojcieszek,Joann Belden,Andrew Feigin,Mary Lou Klimek,Barbara Shannon,William G. Ondo,Christine Hunter,Vincent Calabrese,Paul Atchison,Cathy W. Allen,Frederick J. Marshall,Debra Berry,Irenita Gardiner,Janis M. Miyasaki,Luisa Del Rizzo,Tilak Mendis,Neila Mendis,Peggy Gray,Jean P. Hubble,Karen Betcher,Rajesh Pahwa,Eric Molho,Diane Brown,Lisa M. Shulman,Ali H. Rajput,Marianne Ewanishin,Mark Stacy,Kelli Williamson,John M. Bertoni,Carolyn Peterson,Paul J. Tuite,Brenda Ebbitt,Kathleen M. Shannon,Jean A. Jaglin,Caroline M. Tanner,Kenneth Marek,Karen Stavris,Michael J. Aminoff,Mariann DiMinno,Glenna A. Dowling,Un Jung Kang,Judy Richman,Kapil D. Sethi,W.R. Wayne Martin,Pamela King,Germaine McInnes,Charles H. Adler,Peter A. LeWitt,Maryan DeAngelis,Myrna Schear,Mark Forrest Gordon,Roberta Winnick,Robert G. Feldman,Cathi A. Thomas,Kelly M. Conn,Alicia Brocht,Chris Chadwick,Jeannette Connolly,Susan Daigneault,Shirley Eberly,Janice Bausch,Lee Josephson,Rosemary Oliva,Steven R. Schwid,Anthony E. Lang,Christopher Cox,Carrie Irvine,John G. Nutt,William B. White,Sheila Oren,Ruth Levy,Eli Eyal,David Ladkani,Wayne Houck +89 more
TL;DR: Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
Journal ArticleDOI
IMPLICATIONS OF COMBINED TREATMENT WITH 'MADOPAR' AND L-DEPRENIL IN PARKINSON'S DISEASE: A Long-term Study
TL;DR: It is suggested that L-deprenil may act through inhibition of brain M.A.O. as well as by a psychostimulant effect similar to that of amphetamine which occurs through the release of dopamine to make more dopamine available at dopamine receptor sites.
Journal ArticleDOI
Neuroprotective agents for clinical trials in Parkinson’s disease A systematic assessment
Bernard Ravina,Susan C. Fagan,R. G. Hart,Collin A Hovinga,Diane Murphy,Ted M. Dawson,John R. Marler +6 more
TL;DR: Ravina et al. as discussed by the authors used a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) nonhuman primate model that replicates the progressive nature of PD, and observed that minocycline/MPTP-treated animals developed symptoms more rapidly and severely.
Journal ArticleDOI
DATATOP: A decade of neuroprotective inquiry
TL;DR: Deprenyl 10 mg/day was found to significantly delay the time until enough disability developed to warrant the initiation of levodopa therapy, and this effect was largely sustained during the overall 8.2 years of observation.
Journal ArticleDOI
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan.
Yukihiro Akao,Wakako Maruyama,Shigeomi Shimizu,Hong Yi,Yoshihito Nakagawa,Masayo Shamoto-Nagai,Moussa B.H. Youdim,Yoshihide Tsujimoto,Makoto Naoi +8 more
TL;DR: Rasagiline, N‐propargyl‐1(R)‐aminoindan, which is a now under a clinical trial for Parkinson's disease, suppressed the ΔΨm reduction, release of cytochrome c, and apoptosis induced by NM(R),Sal in SH‐SY5Y cells, proving that rasagILine directly targets the mitochondria also.
Related Papers (5)
A controlled trial of rasagiline in early Parkinson disease: The tempo study
Andrew Siderowf,Matthew B. Stern,Ira Shoulson,Karl Kieburtz,David Oakes,Denni Day,Aileen Shinaman,Sandra Plumb,Stanley Fahn,Karen Blindauer,Mark F. Lew,Howard I. Hurtig,Mary Lloyd,Robert A. Hauser,Lisa Gauger,Lawrence I. Golbe,Joanne Wojcieszek,Joann Belden,Andrew Feigin,Mary Lou Klimek,Barbara Shannon,William G. Ondo,Christine Hunter,Vincent Calabrese,Paul Atchison,Cathy W. Allen,Frederick J. Marshall,Debra Berry,Irenita Gardiner,Janis M. Miyasaki,Luisa Del Rizzo,Tilak Mendis,Neila Mendis,Peggy Gray,Jean P. Hubble,Karen Betcher,Rajesh Pahwa,Eric Molho,Diane Brown,Lisa M. Shulman,Ali H. Rajput,Marianne Ewanishin,Mark Stacy,Kelli Williamson,John M. Bertoni,Carolyn Peterson,Paul J. Tuite,Brenda Ebbitt,Kathleen M. Shannon,Jean A. Jaglin,Caroline M. Tanner,Kenneth Marek,Karen Stavris,Michael J. Aminoff,Mariann DiMinno,Glenna A. Dowling,Un Jung Kang,Judy Richman,Kapil D. Sethi,W.R. Wayne Martin,Pamela King,Germaine McInnes,Charles H. Adler,Peter A. LeWitt,Maryan DeAngelis,Myrna Schear,Mark Forrest Gordon,Roberta Winnick,Robert G. Feldman,Cathi A. Thomas,Kelly M. Conn,Alicia Brocht,Chris Chadwick,Jeannette Connolly,Susan Daigneault,Shirley Eberly,Janice Bausch,Lee Josephson,Rosemary Oliva,Steven R. Schwid,Anthony E. Lang,Christopher Cox,Carrie Irvine,John G. Nutt,William B. White,Sheila Oren,Ruth Levy,Eli Eyal,David Ladkani,Wayne Houck +89 more